Philippe Halfon,  MD, PharmD, PhD, President and founder

Dr Halfon is the founder of several biotechnology companies focusing on antiviral drug discovery and development, including ACTgene, Alphabio, and GenosciencePharma.  He completed a training in Oncogenetic and continue to have a consultation in oncogenetic and infectious Diseases in the European Hospital. He was recently  appointed as Associate Professor in Paris Medical college

Antoine Beret ,CEO

Graduated from Ecole Nationale des Ponts et Chaussées, Ecole Polytechnique. Founder of several successful French biotechnological companies. He Founded Immunotech and served as its Chief Executive Officer until 1998 when Immunotech was acquired by Beckman-Coulter.  From 1999 to 2008 Mr. Beret served as the Chief Executive Officer and President of Trophos. Trophos developped the Olesoxime for Infantile spinal Amyotrophy until Phase 2/3 until the company was recently acquired by Roche for 700 ME.

Firas Bassissi, DVM, PhD, CSO

Dr Bassissi has over 10 years of experience in Research and development. Ph.D in Pharmacokinetics and Toxicology by training. He successfully managed numerous pharmaceutical projects from discovery to clinic phase III in various therapeutic areas at Abbott, Trophos and Avogadro Before joining Genoscience Pharma in 2012, he was DMPK Team Leader in Abbott France. He was strongly involved in research  and development team for drug candidate optimization, PK/PD analyses, regulatory preclinical package defining and therapeutic dose projection in preclinical and clinical phases